BDNF and S100B in psychotic disorders: evidence for an association with treatment responsiveness (Q48593832)

13 February 2018

title

BDNF and S100B in psychotic disorders: evidence for an association with treatment responsiveness (English)

1 reference

13 February 2018

1 reference

Noortje W A van de Kerkhof

1 reference

13 February 2018

Durk Fekkes

1 reference

13 February 2018

Frank M M A van der Heijden

1 reference

13 February 2018

Willem M A Verhoeven

1 reference

13 February 2018

publication date

1 August 2014

1 reference

13 February 2018

published in

Acta Neuropsychiatrica

1 reference

13 February 2018

volume

1 reference

13 February 2018

issue

1 reference

13 February 2018

page(s)

223-229

1 reference

13 February 2018

Diagnostic shifts during the decade following first admission for psychosis

cites work

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Transport of brain-derived neurotrophic factor across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Neurotrophic factors and the pathophysiology of schizophrenic psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Schizophrenia as a disorder of developmentally reduced synaptic connectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Neurodevelopmental trajectories of the human cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Dynamic mapping of human cortical development during childhood through early adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Neurodevelopmental hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

The S100 family of EF-hand calcium-binding proteins: functions and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Brain-derived neurotrophic factor: findings in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Pathophysiological mechanisms for actions of the neurotrophins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Systematic reviews of categorical versus continuum models in psychosis: evidence for discontinuous subpopulations underlying a psychometric continuum. Implications for DSM-V, DSM-VI, and DSM-VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Peripheral markers of blood-brain barrier damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: A positive correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

7 January 2021

Longitudinal brain changes in early-onset psychosis

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

7 January 2021

Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment.

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

7 January 2021

Schizophrenia as a progressive brain disease

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

7 January 2021

Increased serum S100B protein in schizophrenia: a study in medication-free patients

1 reference

https://api.crossref.org/works/10.1017%2FNEU.2013.59

7 January 2021

Identifiers

DOI

10.1017/NEU.2013.59

1 reference

13 February 2018

1 reference

13 February 2018